Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.

Takashi KitagatayaGoki SudaKazunori NagashimaTakehiko KatsuradaKoji YamamotoMegumi KimuraOsamu MaeharaRen YamadaTaku ShigesawaKazuharu SuzukiAkihisa NakamuraMasatsugu OharaMachiko UmemuraNaoki KawagishiMasato NakaiTakuya ShoMitsuteru NatsuizakaKenichi MorikawaKoji OgawaShunsuke OhnishiYoshito KomatsuHiroo HataSatoshi TakeuchiTakashige AbeJun Sakakibara-KonishiTakanori TeshimaAkihiro HommaNaoya Sakamoto

Published in: Journal of gastroenterology and hepatology (2020)

Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis.

Keyphrases

risk factors
combination therapy
open label
clinical trial
newly diagnosed
replacement therapy